4Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108.
5Hampl M. Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines [J]. Minerva Med, 2007, 98(2): 121-130.
6Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006 [J]. CA Cancer J Clin. 2006, 56(1): 11-25, quiz 49-50.
7Guyot A, Karim S, Kyi MS, et al. Evaluation of adjunctive HPV testing by Hybrid Capture Ⅱ in women with minor cytological abnormalities for the diagnosis of CIN2/3 and cost comparison with colposcopy [J]. BMC Infect Dis, 2003, 3: 23.
8Poljak M, Brencic A, Seme K, et al. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer [J]. J Clin Microbiol, 1999, 37 (3) : 796-797.
9Sandri MT, Lentati P, Benini E, et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples [J]. J Clin Microbiol, 2006, 44(6): 2141-2146.
10Carozzi F, Bisanzi S, Sani C, et al. Agreement between the AM- PLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease[J]. J Clin Microbiol, 2007, 45(2): 364-369.
8Schlichte MJ, Guidry J. Current cervical carcinoma screening guidelines[J]. J Clin Med, 2015,4(5) : 918 -932.
9Ferlay F, Autier P, Boniol M, et al. Estimates of the cancer incidenceand mortality in Europe in 2006. Annals Oneol,2007 ,18 :581-592.
10Walboomers JMM,Jacobs MV, ManosmM, et al. Human Papillomavirus is a necessary cause of invasive cervical cancerworldwide. J Pathol, 1999,189 : 12-19.
